Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
17 Feb 2024
17 Feb 2024
Historique:
received:
10
07
2023
accepted:
30
01
2024
medline:
18
2
2024
pubmed:
18
2
2024
entrez:
17
2
2024
Statut:
epublish
Résumé
Zika virus (ZIKV) infection during pregnancy poses significant threats to maternal and fetal health, leading to intrauterine fetal demise and severe developmental malformations that constitute congenital Zika syndrome (CZS). As such, the development of a safe and effective ZIKV vaccine is a critical public health priority. However, the safety and efficacy of such a vaccine during pregnancy remain uncertain. Historically, the conduct of clinical trials in pregnant women has been challenging. Therefore, clinically relevant animal pregnancy models are in high demand for testing vaccine efficacy. We previously reported that a marmoset pregnancy model of ZIKV infection consistently demonstrated vertical transmission from mother to fetus during pregnancy. Using this marmoset model, we also showed that vertical transmission could be prevented by pre-pregnancy vaccination with Zika purified inactivated virus (ZPIV) vaccine. Here, we further examined the efficacy of ZPIV vaccination during pregnancy. Vaccination during pregnancy elicited virus neutralizing antibody responses that were comparable to those elicited by pre-pregnancy vaccination. Vaccination also reduced placental pathology, viral burden and vertical transmission of ZIKV during pregnancy, without causing adverse effects. These results provide key insights into the safety and efficacy of ZPIV vaccination during pregnancy and demonstrate positive effects of vaccination on the reduction of ZIKV infection, an important advance in preparedness for future ZIKV outbreaks.
Identifiants
pubmed: 38368443
doi: 10.1038/s41541-024-00824-0
pii: 10.1038/s41541-024-00824-0
doi:
Types de publication
Journal Article
Langues
eng
Pagination
35Subventions
Organisme : U.S. Department of Defense (United States Department of Defense)
ID : W81XWH-19-2-0020
Organisme : U.S. Department of Defense (United States Department of Defense)
ID : W81XWH-18-2-0040
Organisme : U.S. Department of Defense (United States Department of Defense)
ID : W81XWH-19-2-0020
Organisme : U.S. Department of Defense (United States Department of Defense)
ID : W81XWH-19-2-0020
Organisme : U.S. Department of Defense (United States Department of Defense)
ID : W81XWH-19-2-0020
Organisme : U.S. Department of Defense (United States Department of Defense)
ID : W81XWH-19-2-0020
Organisme : U.S. Department of Defense (United States Department of Defense)
ID : W81XWH-19-2-0020
Organisme : U.S. Department of Health & Human Services | NIH | National Institute on Aging (U.S. National Institute on Aging)
ID : P51OD011133
Informations de copyright
© 2024. The Author(s).
Références
Brasil, P. et al. Zika virus infection in pregnant women in Rio de Janeiro. N. Engl. J. Med. 375, 2321–2334 (2016).
pubmed: 26943629
pmcid: 5323261
doi: 10.1056/NEJMoa1602412
Krauer, F. et al. Zika virus infection as a cause of congenital brain abnormalities and Guillain-Barre Syndrome: systematic review. PLoS Med. 14, e1002203 (2017).
pubmed: 28045901
pmcid: 5207634
doi: 10.1371/journal.pmed.1002203
Costello, A. et al. Defining the syndrome associated with congenital Zika virus infection. Bull. World Health Organ. 94, 406–406A (2016).
pubmed: 27274588
pmcid: 4890216
doi: 10.2471/BLT.16.176990
Cauchemez, S. et al. Association between Zika virus and microcephaly in French Polynesia, 2013-15: a retrospective study. Lancet 387, 2125–2132 (2016).
pubmed: 26993883
pmcid: 4909533
doi: 10.1016/S0140-6736(16)00651-6
Petersen, L. R., Jamieson, D. J. & Honein, M. A. Zika virus. N. Engl. J. Med. 375, 294–295 (2016).
pubmed: 27355409
Gulland, A. Zika virus is a global public health emergency, declares WHO. BMJ 352, i657 (2016).
pubmed: 26839247
doi: 10.1136/bmj.i657
PAHO. www.paho.org (2016).
Musso, D., Ko, A. I. & Baud, D. Zika virus infection - after the pandemic. N. Engl. J. Med. 381, 1444–1457 (2019).
pubmed: 31597021
doi: 10.1056/NEJMra1808246
Cranston, J. S. et al. Association between antenatal exposure to Zika virus and anatomical and neurodevelopmental abnormalities in children. JAMA Netw. Open 3, e209303 (2020).
pubmed: 32633763
pmcid: 7341180
doi: 10.1001/jamanetworkopen.2020.9303
Aguilar Ticona, J. P. et al. Developmental outcomes in children exposed to Zika virus in utero from a Brazilian urban slum cohort study. PLoS Negl. Trop. Dis. 15, e0009162 (2021).
pubmed: 33544730
pmcid: 7891708
doi: 10.1371/journal.pntd.0009162
de Souza, L. et al. Characterizing disabilities in preschool aged children with congenital Zika virus syndrome with the ICF model. Viruses https://doi.org/10.3390/v14102108 (2022).
Wheeler, A. C. Development of infants with congenital Zika syndrome: what do we know and what can we expect? Pediatrics 141, S154–S160 (2018).
pubmed: 29437048
pmcid: 5795516
doi: 10.1542/peds.2017-2038D
Cardoso, T. F. Jr. et al. Congenital Zika infection: neurology can occur without microcephaly. Arch. Dis. Child 104, 199–200 (2019).
pubmed: 29858269
doi: 10.1136/archdischild-2018-314782
Castanha, P. M. S. & Marques, E. T. A. A glimmer of hope: recent updates and future challenges in Zika vaccine development. Viruses https://doi.org/10.3390/v12121371 (2020).
Wang, Y., Ling, L., Zhang, Z. & Marin-Lopez, A. Current advances in Zika vaccine development. Vaccines https://doi.org/10.3390/vaccines10111816 (2022).
Yeasmin, M., Molla, M. M. A., Masud, H. & Saif-Ur-Rahman, K. M. Safety and immunogenicity of Zika virus vaccine: a systematic review of clinical trials. Rev. Med. Virol. 33, e2385 (2023).
pubmed: 35986594
doi: 10.1002/rmv.2385
Gaudinski, M. R. et al. Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials. Lancet 391, 552–562 (2018).
pubmed: 29217376
doi: 10.1016/S0140-6736(17)33105-7
Tebas, P. et al. Safety and immunogenicity of an anti-Zika virus DNA vaccine. N. Engl. J. Med. 385, e35 (2021).
pubmed: 34525286
pmcid: 6824915
doi: 10.1056/NEJMoa1708120
Modjarrad, K. et al. Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials. Lancet 391, 563–571 (2018).
pubmed: 29217375
doi: 10.1016/S0140-6736(17)33106-9
Angelo, K. M. et al. Zika among international travellers presenting to GeoSentinel sites, 2012-2019: implications for clinical practice. J. Travel Med. https://doi.org/10.1093/jtm/taaa061 (2020).
Crespillo-Andujar, C. et al. Characteristics of Zika virus infection among international travelers: a prospective study from a Spanish referral unit. Travel Med. Infect. Dis. 33, 101543 (2020).
pubmed: 31805400
doi: 10.1016/j.tmaid.2019.101543
WHO. Zika Virus Research and Development (R&D) Roadmap, September 2021-Advanced Draft, https://www.who.int/publications/m/item/zika-virus-research-and-development-(r-d)-roadmap (2021).
Narasimhan, H., Chudnovets, A., Burd, I., Pekosz, A. & Klein, S. L. Animal models of congenital zika syndrome provide mechanistic insight into viral pathogenesis during pregnancy. PLoS Negl. Trop. Dis. 14, e0008707 (2020).
pubmed: 33091001
pmcid: 7580937
doi: 10.1371/journal.pntd.0008707
Newman, C., Friedrich, T. C. & O’Connor, D. H. Macaque monkeys in Zika virus research: 1947-present. Curr. Opin. Virol. 25, 34–40 (2017).
pubmed: 28750247
pmcid: 5610623
doi: 10.1016/j.coviro.2017.06.011
Koenig, M. R. et al. Quantitative definition of neurobehavior, vision, hearing and brain volumes in macaques congenitally exposed to Zika virus. PLoS ONE 15, e0235877 (2020).
pubmed: 33091010
pmcid: 7580995
doi: 10.1371/journal.pone.0235877
Haese, N. N. et al. Nonhuman primate models of Zika virus infection and disease during pregnancy. Viruses https://doi.org/10.3390/v13102088 (2021).
Seferovic, M. et al. Experimental Zika virus infection in the pregnant common marmoset induces spontaneous fetal loss and neurodevelopmental abnormalities. Sci. Rep. 8, 6851 (2018).
pubmed: 29717225
pmcid: 5931554
doi: 10.1038/s41598-018-25205-1
Kim, I. J. et al. Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosets. NPJ Vaccines 7, 9 (2022).
pubmed: 35087081
pmcid: 8795414
doi: 10.1038/s41541-021-00426-0
Abbink, P. et al. Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci. Transl. Med. https://doi.org/10.1126/scitranslmed.aao4163 (2017).
Lecouturier, V. et al. An optimized purified inactivated Zika vaccine provides sustained immunogenicity and protection in cynomolgus macaques. NPJ Vaccines 5, 19 (2020).
pubmed: 32194996
pmcid: 7067768
doi: 10.1038/s41541-020-0167-8
Stephenson, K. E. et al. Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial. Lancet Infect. Dis. 20, 1061–1070 (2020).
pubmed: 32618279
pmcid: 7472641
doi: 10.1016/S1473-3099(20)30085-2
Koren, M. A. et al. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(23)00192-5 (2023).
Fuke, Y. et al. Clinical significance and treatment of massive intervillous fibrin deposition associated with recurrent fetal growth retardation. Gynecol. Obstet. Invest. 38, 5–9 (1994).
pubmed: 7959327
doi: 10.1159/000292434
Spinillo, A. et al. The impact of placental massive perivillous fibrin deposition on neonatal outcome in pregnancies complicated by fetal growth restriction. Placenta 87, 46–52 (2019).
pubmed: 31546153
doi: 10.1016/j.placenta.2019.09.007
Lampi, K., Papadogiannakis, N., Sirotkina, M., Pettersson, K. & Ajne, G. Massive perivillous fibrin deposition of the placenta and pregnancy outcome: a retrospective observational study. Placenta 117, 213–218 (2022).
pubmed: 34959167
doi: 10.1016/j.placenta.2021.12.013
Katzman, P. J. & Genest, D. R. Maternal floor infarction and massive perivillous fibrin deposition: histological definitions, association with intrauterine fetal growth restriction, and risk of recurrence. Pediatr. Dev. Pathol. 5, 159–164 (2002).
pubmed: 11910510
doi: 10.1007/s10024001-0195-y
Bane, A. L. & Gillan, J. E. Massive perivillous fibrinoid causing recurrent placental failure. BJOG 110, 292–295 (2003).
pubmed: 12628270
doi: 10.1046/j.1471-0528.2003.00119.x
Redline, R. W. Placental pathology: a neglected link between basic disease mechanisms and untoward pregnancy outcome. Curr. Opin. Obstet. Gynecol. 7, 10–15 (1995).
pubmed: 7742508
doi: 10.1097/00001703-199507010-00003
Mor, G. & Cardenas, I. The immune system in pregnancy: a unique complexity. Am. J. Reprod. Immunol. 63, 425–433 (2010).
pubmed: 20367629
pmcid: 3025805
doi: 10.1111/j.1600-0897.2010.00836.x
Collier, A. Y. et al. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. JAMA 325, 2370–2380, (2021).
pubmed: 33983379
doi: 10.1001/jama.2021.7563
Kim, I. J. et al. Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice. npj Vaccines 9, 32 (2024).
Cornish, E. F., McDonnell, T. & Williams, D. J. Chronic inflammatory placental disorders associated with recurrent adverse pregnancy outcome. Front. Immunol. 13, 825075 (2022).
pubmed: 35529853
pmcid: 9072631
doi: 10.3389/fimmu.2022.825075
Abu-Raya, B., Michalski, C., Sadarangani, M. & Lavoie, P. M. Maternal immunological adaptation during normal pregnancy. Front. Immunol. 11, 575197 (2020).
pubmed: 33133091
pmcid: 7579415
doi: 10.3389/fimmu.2020.575197
Albrecht, M. & Arck, P. C. Vertically transferred immunity in neonates: mothers, mechanisms and mediators. Front. Immunol. 11, 555 (2020).
pubmed: 32296443
pmcid: 7136470
doi: 10.3389/fimmu.2020.00555
Mackin, D. W. & Walker, S. P. The historical aspects of vaccination in pregnancy. Best. Pr. Res Clin. Obstet. Gynaecol. 76, 13–22 (2021).
doi: 10.1016/j.bpobgyn.2020.09.005
Etti, M. et al. Maternal vaccination: a review of current evidence and recommendations. Am. J. Obstet. Gynecol. 226, 459–474 (2022).
pubmed: 34774821
doi: 10.1016/j.ajog.2021.10.041
Zaman, K. et al. Effectiveness of maternal influenza immunization in mothers and infants. N. Engl. J. Med. 359, 1555–1564 (2008).
pubmed: 18799552
doi: 10.1056/NEJMoa0708630
Malek, A., Sager, R., Kuhn, P., Nicolaides, K. H. & Schneider, H. Evolution of maternofetal transport of immunoglobulins during human pregnancy. Am. J. Reprod. Immunol. 36, 248–255 (1996).
pubmed: 8955500
doi: 10.1111/j.1600-0897.1996.tb00172.x
Palmeira, P., Quinello, C., Silveira-Lessa, A. L., Zago, C. A. & Carneiro-Sampaio, M. IgG placental transfer in healthy and pathological pregnancies. Clin. Dev. Immunol. 2012, 985646 (2012).
pubmed: 22235228
doi: 10.1155/2012/985646
Jaquish, C. E., Toal, R. L., Tardif, S. D. & Carson, R. L. Use of ultrasound to monitor prenatal growth and development in the common marmoset (Callithrix jacchus). Am. J. Primatol. 36, 259–275 (1995).
pubmed: 31924098
doi: 10.1002/ajp.1350360402
Tardif, S. D., Jaquish, C. E., Toal, R. L., Layne, D. G. & Power, R. A. Estimation of gestational ages in the common marmoset (Callithrix jacchus) from published prenatal growth curves. J. Med. Primatol. 27, 28–32 (1998).
pubmed: 9606040
doi: 10.1111/j.1600-0684.1998.tb00065.x
Kim, I. J. et al. Impact of prior dengue virus infection on Zika virus infection during pregnancy in marmosets. Sci. Transl. Med. 15, eabq6517 (2023).
pubmed: 37285402
doi: 10.1126/scitranslmed.abq6517
Layne, D. G. & Power, R. A. Husbandry, handling, and nutrition for marmosets. Comp. Med. 53, 351–359 (2003).
pubmed: 14524410
Szaba, F. M. et al. Zika virus infection in immunocompetent pregnant mice causes fetal damage and placental pathology in the absence of fetal infection. PLoS Pathog. 14, e1006994 (2018).
pubmed: 29634758
pmcid: 5909921
doi: 10.1371/journal.ppat.1006994
Lanciotti, R. S. et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14, 1232–1239 (2008).
pubmed: 18680646
pmcid: 2600394
doi: 10.3201/eid1408.080287